Welcome to our dedicated page for NTUS news (Ticker: NTUS), a resource for investors and traders seeking the latest updates and insights on NTUS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NTUS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NTUS's position in the market.
Natus Medical Incorporated (NASDAQ: NTUS) plans to release its 2021 first quarter financial results on May 6, 2021, after market close. A conference call will follow the release at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and answer questions. Interested parties can join the call by dialing the provided numbers. A replay will be accessible for 48 hours post-call and a recording will be available on the company’s website for 90 days.
Natus Medical reported Q4 2020 revenue of $118.7 million, down 9.7% year-over-year. The company achieved a 15.5% increase from Q3, generating $16.3 million in operating cash flow and reducing debt by $10 million. GAAP EPS was $0.15, while non-GAAP EPS was $0.39. For FY 2020, revenue declined 16.1% to $415.7 million. Natus projects Q1 2021 revenue between $108 million and $112 million, with non-GAAP EPS expected between $0.11 and $0.18.
Natus Medical Incorporated (NASDAQ:NTUS) updated its fourth quarter 2020 revenue guidance, now expecting between $118.0 million and $119.0 million, an increase from the prior forecast of $104.0 million to $114.0 million. The company did not revise earnings per share guidance, which will be detailed in the February 25, 2021 earnings release. CEO Jonathan Kennedy will present at the virtual 39th Annual JP Morgan Healthcare Conference on January 14 and the 23rd Annual Needham Growth Conference on January 15, 2021.
Natus Medical (NASDAQ: NTUS) will announce its 2020 fourth-quarter financial results on February 25, 2021, after market close. The management will host a conference call at 1:30 p.m. PT to discuss the results and address investor questions. Interested individuals can participate by calling 1-844-634-1441 (domestic) or 1-508-637-5658 (international). A telephone replay will be available for 48 hours post-call. The call will also be streamed online.
Natus specializes in medical device solutions for central nervous and sensory system disorders.
Natus Medical, a provider of medical devices for central nervous and sensory system disorders, announced that Drew Davies, CFO, will present at the 13th Annual LD Micro Conference. The presentation is scheduled for December 14, 2020, at 12:40 p.m. ET (9:40 a.m. PT). This event highlights Natus's ongoing commitment to advancing medical technology and improving patient care across different age groups.
Natus Medical Incorporated (NASDAQ:NTUS) announced the acquisition of Babybe GmbH, enhancing its Newborn Care portfolio with patented remote mother-to-baby communication technology. This innovation enables real-time connection between mothers and premature infants in NICU through heartbeat, breathing, and vocal sounds. Clinical studies are ongoing to evaluate the technology's impact on neonatal health. With 15 million premature births annually, Natus sees significant market potential, expecting Babybe products to be commercially available by early 2022.
Natus Medical reported Q3-2020 financial results with revenue of $102.8 million, a 16.8% decline year-over-year. However, revenue increased 21.3% from Q2-2020. The GAAP net loss was $9.3 million, or $0.28 per share, compared to a profit in Q3-2019. Non-GAAP earnings were $0.09 per share. The company reduced debt by $20 million and generated $7.5 million in operating cash flow. For Q4-2020, revenue guidance is between $104 million and $114 million, expecting sequential growth across all markets.
Natus Medical Incorporated (NASDAQ: NTUS) will release its third quarter financial results on October 29, 2020, after market close. Management will host a conference call at 1:30 PM PT (4:30 PM ET) to discuss these results. Interested parties can join the call by dialing 1-844-634-1441 domestically or 1-508-637-5658 internationally, using reservation code 7889667. An online stream will also be available, and a recording can be accessed for 90 days post-call.
Natus Medical, a key player in medical device solutions for nervous and sensory disorders, announced a series of one-on-one meetings with institutional investors. Scheduled for September 14, 2020, during the Morgan Stanley Virtual 18th Annual Global Healthcare Conference, these meetings will be led by CEO Jonathan Kennedy and CFO Drew Davies. Investors interested in participating should reach out to a Morgan Stanley representative. Natus continues to focus on delivering innovative solutions for patients of all ages.
Natus Medical reported Q2 2020 revenue of $84.8 million, a 32.4% decrease from $125.5 million in Q2 2019. GAAP loss per share was $0.26, compared to a profit of $0.10 in the prior year. The company saw a 1% growth in its Newborn Care segment, but revenue declines were attributed to COVID-19 impacts on Neuro and Hearing & Balance markets. While operational measures were implemented to ensure safety, the company expects improvements in Q3 2020, although significant uncertainty remains due to the pandemic.
FAQ
What is the market cap of NTUS (NTUS)?
